252 related articles for article (PubMed ID: 7108208)
21. Activation of macrophage cytostatic and cytotoxic activity in vitro by liposomes containing a new lipophilic muramyl peptide derivative, MDP-L-alanyl-cholesterol (MTP-CHOL).
Phillips NC; Moras ML; Chedid L; Petit JF; Tenu JP; Lederer E; Bernard JM; Lefrancier P
J Biol Response Mod; 1985 Oct; 4(5):464-74. PubMed ID: 3935756
[TBL] [Abstract][Full Text] [Related]
22. The activation of tumoricidal properties in human blood monocytes by muramyl dipeptide requires specific intracellular interaction.
Fogler WE; Fidler IJ
J Immunol; 1986 Mar; 136(6):2311-7. PubMed ID: 2936824
[TBL] [Abstract][Full Text] [Related]
23. Production of a tumor cytolytic factor(s) by activated human alveolar macrophages and its action.
Sone S; Tachibana K; Ishii K; Ogawara M; Tsubura E
Cancer Res; 1984 Feb; 44(2):646-51. PubMed ID: 6692369
[TBL] [Abstract][Full Text] [Related]
24. Isolation of tumoricidal macrophages from lung melanoma metastases of mice treated systemically with liposomes containing a lipophilic derivative of muramyl dipeptide.
Key ME; Talmadge JE; Fogler WE; Bucana C; Fidler IJ
J Natl Cancer Inst; 1982 Nov; 69(5):1198-98. PubMed ID: 6957661
[TBL] [Abstract][Full Text] [Related]
25. Differential effects of liposome-incorporation on liver macrophage activating potencies of rough lipopolysaccharide, lipid A, and muramyl dipeptide. Differences in susceptibility to lysosomal enzymes.
Daemen T; Veninga A; Dijkstra J; Scherphof G
J Immunol; 1989 Apr; 142(7):2469-74. PubMed ID: 2926140
[TBL] [Abstract][Full Text] [Related]
26. Effect of cisplatin, lipopolysaccharide, muramyl dipeptide and recombinant interferon-gamma on murine macrophages in vitro. I. Macrophage-mediated tumor cell lysis.
Geetha B; Sodhi A
Nat Immun Cell Growth Regul; 1989; 8(2):100-7. PubMed ID: 2503714
[TBL] [Abstract][Full Text] [Related]
27. Comparative effect of muramyl dipeptide in vivo and in vitro on the tumoricidal activity of rat peritoneal macrophages.
Reisser D; Jeannin JF; Lagadec P; Martin F
J Biol Response Mod; 1985 Oct; 4(5):460-3. PubMed ID: 4078593
[TBL] [Abstract][Full Text] [Related]
28. Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide.
Fidler IJ; Sone S; Fogler WE; Barnes ZL
Proc Natl Acad Sci U S A; 1981 Mar; 78(3):1680-4. PubMed ID: 6940181
[TBL] [Abstract][Full Text] [Related]
29. Activation of murine Kupffer cell tumoricidal activity by liposomes containing lipophilic muramyl dipeptide.
Phillips NC; Rioux J; Tsao MS
Hepatology; 1988; 8(5):1046-50. PubMed ID: 2971013
[TBL] [Abstract][Full Text] [Related]
30. Tumor cell binding and induction of endothelial cell tumoricidal activity in vitro by muramyl dipeptide is enhanced by liposomal encapsulation.
Phillips NC; Stewart-Phillips J; Wang P
J Immunother Emphasis Tumor Immunol; 1994 Apr; 15(3):185-93. PubMed ID: 8032541
[TBL] [Abstract][Full Text] [Related]
31. Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide.
Kleinerman ES; Erickson KL; Schroit AJ; Fogler WE; Fidler IJ
Cancer Res; 1983 May; 43(5):2010-4. PubMed ID: 6831430
[TBL] [Abstract][Full Text] [Related]
32. The in situ induction of tumoricidal activity in alveolar macrophages by liposomes containing muramyl dipeptide is a thymus-independent process.
Fidler IJ
J Immunol; 1981 Oct; 127(4):1719-20. PubMed ID: 6974201
[No Abstract] [Full Text] [Related]
33. Functional characteristics of the rat liver macrophage population after a single intravenous injection of liposome-encapsulated muramyl peptides.
Hoedemakers RM; Vossebeld PJ; Daemen T; Scherphof GL
J Immunother Emphasis Tumor Immunol; 1993 May; 13(4):252-60. PubMed ID: 8334109
[TBL] [Abstract][Full Text] [Related]
34. Induction of antibodies directed against self and altered-self determinants by a synthetic adjuvant, muramyl dipeptide and some of its derivatives.
Löwy I; Leclerc C; Chedid L
Immunology; 1980 Mar; 39(3):441-50. PubMed ID: 6160092
[TBL] [Abstract][Full Text] [Related]
35. Comparative interaction of free and liposome-encapsulated nor-muramyl dipeptide or muramyl tripeptide phosphatidylethanolamine (3H-labelled) with human blood monocytes.
Fogler WE; Fidler IJ
Int J Immunopharmacol; 1987; 9(2):141-50. PubMed ID: 3583507
[TBL] [Abstract][Full Text] [Related]
36. Lack of production of interleukin 1 by human blood monocytes activated to the antitumor state by liposome-encapsulated muramyl tripeptide.
Tandon P; Utsugi T; Sone S
Cancer Res; 1986 Oct; 46(10):5039-44. PubMed ID: 3489519
[TBL] [Abstract][Full Text] [Related]
37. Uptake of liposomes and liposome-encapsulated muramyl dipeptide by human peripheral blood monocytes.
Mehta K; Lopez-Berestein G; Hersh EM; Juliano RL
J Reticuloendothel Soc; 1982 Aug; 32(2):155-64. PubMed ID: 7161762
[TBL] [Abstract][Full Text] [Related]
38. Protective effect of neoglycoprotein-conjugated muramyl dipeptide against Leishmania donovani infection: the role of cytokines.
Sarkar K; Das PK
J Immunol; 1997 Jun; 158(11):5357-65. PubMed ID: 9164956
[TBL] [Abstract][Full Text] [Related]
39. Modulation of pulmonary macrophage superoxide release and tumoricidal activity following activation by biological response modifiers.
Drath DB
Immunopharmacology; 1986 Oct; 12(2):117-26. PubMed ID: 3021650
[TBL] [Abstract][Full Text] [Related]
40. Activation of tumoricidal properties in murine macrophages by intravenous injection of muramyl dipeptide encapsulated within liposomes as a treatment for spontaneous metastasis.
Fidler IJ; Poste G
Prog Clin Biol Res; 1981; 75B():257-67. PubMed ID: 7323097
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
